NCT03068416View on ClinicalTrials.gov

CD19-targeting, 3rd Generation CAR T Cells for Refractory B Cells Malignancy

PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

September 18, 2017

Primary Completion Date

August 19, 2021

Study Completion Date

August 19, 2021

Conditions
B-cell LeukemiaB-Cell Lymphoma
Interventions
BIOLOGICAL

CAR T cells

Autologous CD19-targeting, 3rd generation CAR T cells

Trial Locations (1)

75185

Uppsala University Hospital, Dept of Oncology, Uppsala

All Listed Sponsors
collaborator

Uppsala University Hospital

OTHER

collaborator

AFA Insurance

INDUSTRY

lead

Uppsala University

OTHER

NCT03068416 - CD19-targeting, 3rd Generation CAR T Cells for Refractory B Cells Malignancy | Biotech Hunter | Biotech Hunter